Carregant...
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
A benefit of temozolomide (TMZ) is that myelotoxicity is uncommon. Recently, several small series have reported significant myelotoxicity resulting in treatment delays or death. The ability to predict risk of myelotoxicity may influence patient care. We retrospectively reviewed 680 malignant glioma...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Duke University Press
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2802402/ https://ncbi.nlm.nih.gov/pubmed/19179423 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-120 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|